Teva Pharmaceutical Industries Limited logo

Teva Pharmaceutical Industries LimitedNYSE: TEVA

Profile

Sector:

Healthcare

Country:

Israel

IPO:

16 February 1982

Next earnings report:

06 November 2024

Last dividends:

27 November 2017

Next dividends:

N/A
$20.93 B
-2%vs. 3y high
96%vs. sector
-vs. 3y high
-vs. sector
-2%vs. 3y high
72%vs. sector
-3%vs. 3y high
27%vs. sector

Price

regular market | 4 min ago
$18.48+$0.03(+0.14%)

Dividend

No data over the past 3 years
$4.16 B$4.12 B
$4.16 B-$846.00 M

Analysts recommendations

Institutional Ownership

TEVA Latest News

Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
globenewswire.com01 November 2024 Sentiment: -

TEL AVIV, Israel and PARSIPPANY, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new patient- and physician-reported interim results from the Phase 4 IMPACT-TD Registry study, revealing differences between TD patients with a psychotic disorder and those with a mood disorder. The IMPACT-TD Registry is the largest study of its kind evaluating the holistic effects of TD, showing real-world treatment patterns and outcomes with once-daily AUSTEDO® XR® (deutetrabenazine) extended-release tablets and twice-daily AUSTEDO (deutetrabenazine) tablets. Teva also announced interim data from a patient-reported survey describing early, real-world experience with AUSTEDO XR. These findings are being presented at the Psych Congress 2024 taking place from October 29 – November 2 in Boston, MA.

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone)
globenewswire.com01 November 2024 Sentiment: POSITIVE

TEL AVIV, Israel & PARSIPPANY, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new, positive data on social functioning and quality of life from the Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS) trial evaluating TEV-'749 in adult patients diagnosed with schizophrenia. In the acute treatment phase of the study (Period 1), TEV-'749 demonstrated significant improvement in social functioning and quality of life across multiple validated measures from baseline to week 8. The systemic safety profile of TEV-'749 was consistent with other approved oral formulations of olanzapine, with no new safety signals identified and no PDSS events reported to date.1 In addition, in vitro data and interim results from a Phase 1 study evaluating the pharmacokinetic characteristics of TEV-'749 validate that its route of administration and drug delivery technology may effectively address the risk of PDSS development.1 These studies, highlighting the patient focused outcomes, were presented at Psych Congress 2024 taking place from October 29 – November 2, 2024, in Boston, MA.

Countdown to Teva Pharmaceutical Industries (TEVA) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
zacks.com01 November 2024 Sentiment: POSITIVE

Evaluate the expected performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Teva Statement on European Commission Decision; Company to Appeal
globenewswire.com31 October 2024 Sentiment: NEUTRAL

TEL AVIV, Israel, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals Industries Ltd. (NYSE: and TASE: TEVA) is responding to the European Decision following its investigation into the company's practices regarding COPAXONE® -- the standard-of-care treatment for multiple sclerosis – and announcing its intention to appeal the judgement and fine imposed.

Teva: Great Time To Buy Leading Generic Drugmaker With Growth Indicators And Lower Debt
seekingalpha.com23 October 2024 Sentiment: POSITIVE

Teva gets a buy rating as it trades well below 10-year highs and shows growth potential as the leading global generic drugmaker. Their drug pipeline is robust and diverse, as well as existing drugs on the market across multiple clinical segments, including cancer drugs. Debt to equity is high vs peers; however, debt is on a declining trend.

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA
globenewswire.com08 October 2024 Sentiment: POSITIVE

TEL AVIV, Israel, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the United States (U.S.) Food and Drug Administration (FDA) has accepted, and the European Medicines Agency (EMA) has validated, applications for TVB-009P, a biosimilar candidate to Prolia® (denosumab).1

Is Teva Pharmaceutical Industries (TEVA) Stock Outpacing Its Medical Peers This Year?
zacks.com07 October 2024 Sentiment: NEUTRAL

Here is how Teva Pharmaceutical Industries Ltd. (TEVA) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate
globenewswire.com03 October 2024 Sentiment: POSITIVE

TEL AVIV, ISRAEL and MADRID, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, today announced a new global licensing agreement for the development of an anti PD-1 oncology biosimilar candidate. This marks the second agreement between the two companies, reinforcing the solid foundation of the collaborative efforts that commenced in April 2024.

Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.
globenewswire.com01 October 2024 Sentiment: POSITIVE

PARSIPPANY, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of the first and only generic version of Sandostatin®1 LAR Depot, in the United States.

Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024
globenewswire.com30 September 2024 Sentiment: POSITIVE

TEL AVIV, Israel, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its financial results for the third quarter of 2024 on Wednesday, November 6, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.

What type of business is Teva Pharmaceutical Industries Limited?

Teva Pharmaceutical Industries Limited is a multinational pharmaceutical company headquartered in Petah Tikva, Israel. The company specializes in producing generic drugs, active pharmaceutical ingredients, and to a lesser extent, proprietary drugs. The company ranks 16th in the list of the largest pharmaceutical manufacturers and 704th in the ranking of the largest global companies by Forbes Global 2000. Teva has 80 plants in its portfolio and operates in 60 countries. Teva is a member of the American Association of Pharmaceutical Researchers and Manufacturers.

What sector is Teva Pharmaceutical Industries Limited in?

Teva Pharmaceutical Industries Limited is in the Healthcare sector

What industry is Teva Pharmaceutical Industries Limited in?

Teva Pharmaceutical Industries Limited is in the Drug Manufacturers - Specialty & Generic industry

What country is Teva Pharmaceutical Industries Limited from?

Teva Pharmaceutical Industries Limited is headquartered in Israel

When did Teva Pharmaceutical Industries Limited go public?

Teva Pharmaceutical Industries Limited initial public offering (IPO) was on 16 February 1982

What is Teva Pharmaceutical Industries Limited website?

https://www.tevapharm.com

Is Teva Pharmaceutical Industries Limited in the S&P 500?

No, Teva Pharmaceutical Industries Limited is not included in the S&P 500 index

Is Teva Pharmaceutical Industries Limited in the NASDAQ 100?

No, Teva Pharmaceutical Industries Limited is not included in the NASDAQ 100 index

Is Teva Pharmaceutical Industries Limited in the Dow Jones?

No, Teva Pharmaceutical Industries Limited is not included in the Dow Jones index

When was Teva Pharmaceutical Industries Limited the previous earnings report?

No data

When does Teva Pharmaceutical Industries Limited earnings report?

The next expected earnings date for Teva Pharmaceutical Industries Limited is 06 November 2024